1. PCP Perspectives Clinical Considerations in Hyperkalemia

3. Clinical Aspects of Hyperkalemia

4. RAAS Inhibitors in Hyperkalemia

7. Aldosterone Antagonists in Heart Failure Clinical Trial Findings

9. Predictors of Hyperkalemia[a]

10. Standard Care of Acute Hyperkalemia

11. Hyperkalemia Management

12. Management of Chronic Hyperkalemia Overview

13. High-Potassium-Containing Foods

14. Medications Associated With Hyperkalemia

15. Diuretic Use in the Management of Chronic Hyperkalemia

16. Sodium Polystyrene Sulfonate

17. Patiromer

18. Opal-HK Phase 3 Trial Study Design

19. Initial Treatment Phase Demographics and Baseline Characteristics

20. Baseline RAAS Inhibitor and Diuretic Medications

21. Initial Treatment Phase Primary and Secondary Efficacy Endpoints

22. Randomized Withdrawal Phase Time to First Recurrent Hyperkalemia Event*

23. Initial Treatment Phase Adverse Events While Taking Patiromer

24. Investigational Potassium Binder ZS-9*

25. HARMONIZE Study Design

26. HARMONIZE Study Population Baseline Characteristics

27. HARMONIZE TRIAL Serum K+ Levels During Randomized Phase (Days 8-29)

28. ZS-9 Adverse Events

29. Summary of Current Management

30. Providing Patient Education

31. Concluding Remarks

32. Abbreviations (cont)

33. Abbreviations (cont)